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A B S T R A C T
Hot melt extrusion has gained considerable attention as a novel technique for taste masking of bitter APIs.
The aim of this study was to investigate whether hot melt extrusion could be used to develop taste
masked formulations of isoniazid and also to evaluate and correlate different taste assessment methods
Two polymers with different physico-chemical properties, Soluplus and Eudragit E-PO were chosen as
carriers for the drug. Eudragit E-PO has already been widely used for taste masking due to its selective
release properties, while Soluplus has not been studied in this regard but provides a useful comparator of
a polymer that should release the drug reasonably efﬁciently. Polymeric formulations of isoniazid were
produced with drug loadings of 20% and 30% w/w. The solid state characteristics of the formulations were
assessed by differential scanning calorimetry and powder X-ray diffraction. The taste of isoniazid was
assessed using the rodent Brief Access Taste Aversion (BATA) model, while formulations were assessed
using the electronic tongue and dissolution under simulated oral conditions. Investigation into the drug
loading effect with these two polymers showed that all Soluplus based extrudates with drug loading up
to 30% w/w were fully amorphous while Eudragit E-PO based extrudates contained crystalline drug as
demonstrated by both DSC and PXRD, dependent on loading. BATA testing of isoniazid gave an IC50 value,
i.e. the dose of drug which inhibits 50% of licks, of 11.1 mg/mL. Taste assessment of the formulations using
both simulated oral drug release and the electronic tongue demonstrated that Eudragit E-PO based
formulations had a better taste masking efﬁciency than Soluplus. This is due to the fact that signiﬁcantly
less isoniazid is released from the Eudragit E-PO based formulations under oral conditions.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
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journal homepage: www.elsev ier .com/locate / i jpharm1. Introduction
A signiﬁcant number of drugs currently on the market or under
development have poor organoleptic properties which, unless
formulated appropriately, can be very unpalatable. Therefore, taste
masking has become an important part of the formulation
development process, particularly for paediatric medications.
There are a wide range of formulating strategies that can be used
either alone or in combination to mask the bitter taste of a drug,
including but not limited to: use of ﬂavours and sweeteners
(Albertini et al., 2004; de Aguiar et al., 2010; Fini et al., 2008;
Harada et al., 2010), lipophilic vehicles (Nitanai et al., 2012; Qi et al.,* Corresponding author.
E-mail address: duncan.craig@ucl.ac.uk (D.Q.M. Craig).
http://dx.doi.org/10.1016/j.ijpharm.2017.07.008
0378-5173/© 2017 The Authors. Published by Elsevier B.V. This is an open access artic
Please cite this article in press as: A.V. Keating, et al., Solid state charac
extrudates of isoniazid for paediatric administration, Int J Pharmaceut 2008a; Vaassen et al., 2012), salt formation (Aitipamula et al., 2014;
Rahman et al., 2012), solid dispersions (Du et al., 2013; Kulkarni
and Amin, 2008; Tan et al., 2013), salting out layers (Yoshida et al.,
2009, 2008), ion exchange resins (Agresti et al., 2008; Bhise et al.,
2008; Yewale et al., 2013; Yu et al., 2012), complexation with
cyclodextrins (Arima et al., 2012; Nieddu et al., 2014; Orlu-Gul
et al., 2013; Preis et al., 2014), or ﬁlm coating (Joshi and Petereit,
2013).
In recent years hot melt extrusion (HME) has emerged as a
novel processing method for taste masking of bitter drugs
(Maniruzzaman et al., 2014). HME is a very versatile technique
which has already been used by the pharmaceutical industry to
produce a variety of formulations including pellets, oral fast
dissolving ﬁlms, controlled release tablets, transdermal/-mucosal
delivery systems and implants (Wilson et al., 2012). There are
many advantages of using this approach over traditionalle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
terisation and taste masking efﬁciency evaluation of polymer based
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organic solvents is a common issue with many pharmaceutical
techniques, in particular when producing medicines for children
who can be more sensitive to the toxic effect of solvents than adults
(Walsh et al., 2014). Hot melt extrusion is a solvent free process,
thus avoiding the need for this step and also making it an
environmentally friendly process. It is also a continuous process
which is relatively simple to scale up (Maniruzzaman et al., 2014),
and can be adapted to meet the goals of the FDA process analytical
technology scheme for quality by design in pharmaceutical
products (Saerens et al., 2014).
The taste of medicines can be assessed using in vivo or in vitro
methods (Mohamed-Ahmed et al., 2016). In vivo taste assessment
methods involve using either humans or animals to assess the taste
of substances. Human taste panel studies involve evaluating the
taste of medicines or dosage forms by estimating the gustatory
sensation responses in healthy adult human volunteers (Schiffman
et al., 2000). Animal models such as mice, rats and dogs may also
be used to assess taste. The rodent Brief-Access Taste Aversion
(BATA) model is an in vivo taste assessment tool that has shown
great promise in assessing the taste of Active Pharmaceutical
Ingredients (APIs) with comparable results to human taste panel
data (Devantier et al., 2008; Rudnitskaya et al., 2013). In this animal
taste model, rodents, most often mice or rats (Soto et al., 2015), are
mildly water-deprived and then put in an apparatus known as a
‘lickometer’ that records the number of licks that the rodents make
to different concentrations of the API under assessment. A high
number of licks will indicate that the solution is palatable whereas
a low number of licks compared to water will indicate an aversive
taste. With this procedure, a full concentration-response curve of
lick rate can be obtained over a short period of time using very few
animals.
In recent years in vitro methods such as electronic tongue
systems have been developed as novel methods for taste
assessment. Electronic tongue systems are sensor array based
robotic systems which can be used for the assessment of single
substances as well as complex mixtures of substances. There are
two commercially available electronic tongues, the Alpha MOS
Astree electronic tongue and the Insent TS-5000Z taste sensing
system. When a molecule interacts with an electronic tongue
sensor there is a change in the electrical potential of the sensor. The
response of the sensors depends logarithmically on the activity of
the substances which are measured in a way analogous to that of
human taste (Woertz et al., 2011).
Isoniazid is a highly bactericidal drug which is used to treat
tuberculosis in both paediatric and adult populations (Donald and
Schaaf, 2007). It is a borderline BCS Class I/III drug (Becker et al.,
2007), with an aqueous solubility of approximately 125 mg/mL
(Nair et al., 2011), which has been found to be close to 100%
bioavailable under most circumstances (Isoniazid, 2008). Isoniazid
is used in both the intensive and continuation phases of TB
treatment, meaning that patients typically have to take the drug
for a minimum of six months. It is a bitter tasting drug which,
coupled with long treatment regimens, tends to lead to poor
patient adherence particularly in paediatric populations (Ruth-Table 1
Formulations and extrusion parameters used for hot melt extrusion.
Isoniazid (% w/w) Soluplus (% w/w) Eudragit E
20 80 – 
30 70 – 
20 – 80 
30 – 70 
Please cite this article in press as: A.V. Keating, et al., Solid state charac
extrudates of isoniazid for paediatric administration, Int J Pharmaceut erford et al., 2012). It is hoped that by developing an age
appropriate, taste masked formulation of this drug that patient
adherence and thus treatment outcome will be improved.
As mentioned previously, isoniazid has been found to have close
to 100% bioavailablility, thus it is essential that any taste masking
strategy used does not adversely affect absorption, hence the
formulations must undergo rapid dissolution in the stomach. For
this reason, two polymers which are known to have rapid gastric
release proﬁles were chosen, i.e. Eudragit E-PO and Soluplus.
Eudragit E-PO is a cationic copolymer based on dimethylami-
noethyl methacrylate, butyl methacrylate, and methyl methacry-
late which is insoluble above pH 5 (Qi et al., 2008b). It has been
extensively used previously in the pharmaceutical industry as a
taste-masking excipient (Thakral et al., 2013). Soluplus is a
polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol
graft copolymer which is freely water soluble (Fule et al., 2013; Fule
and Amin, 2014; Shah et al., 2013). It has not yet been widely used
for taste masking applications, but also provides a means of
comparing the efﬁcacy of Eudragit E-PO from a comparable HME
formulation. By using these two matrix systems we intend to
examine the correlation between polymer water miscibility, solid
state structure, in vitro drug release and taste masking efﬁciency.
2. Materials and methods
2.1. Materials
Isoniazid, potassium chloride, potassium hydroxide, tartaric
acid, potassium phosphate monobasic, sodium chloride, calcium
chloride and sodium hydroxide were obtained from Sigma Aldrich
(UK). Soluplus was kindly donated by BASF (Ludwigshafen,
Germany). Eudragit E-PO was obtained from Röhm GmbH & Co.
(Sontheim/Brenz, Germany). Hydrochloric acid was obtained from
Fisher Chemicals (Loughborough, UK). Distilled water was used for
all experiments. All substances were used as received unless stated
otherwise.
2.2. Hot melt extrusion
Hot-melt extrudates were prepared using a Thermo Scientiﬁc
Process 11 co-rotating twin screw extruder (ThermoScientiﬁc, UK)
ﬁtted with a round die (die diameter: 2 mm). The formulations and
optimised extrusion parameters used are given in Table 1. Post
extrusion the extrudates were cut into 1 mm pieces using a
Pharma 11 Varicut Pelletizer (Thermo Fisher Scientiﬁc, U.K.).
2.3. Determination of drug loading
A 0.1% w/v solution of each extrudate was prepared by
dissolving 10 mg of ground extrudate in 10 mL ethanol. The
mixtures were sonicated (XUBA3 ultrasonic bath, Grant Instru-
ments Ltd., Cambridgeshire, UK) for 30 min to ensure complete
dissolution of the extrudate. Each solution was diluted 1 in 10
before the UV absorbance was recorded at 263 nm using a JenwayPO (% w/w) Temperature (C) Speed (rpm)
140 50
140 50
130 50
130 50
terisation and taste masking efﬁciency evaluation of polymer based
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Table 2
Composition of Simulated Salivary Fluid.47
Compound Concentration
Potassium phosphate monobasic 12 mM
Sodium chloride 40 mM
Calcium chloride 1.5 mM
Sodium hydroxide to pH 7.4
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UK) where the polymers showed no absorbance.
2.4. Differential scanning calorimetry (DSC)
Modulated temperature DSC thermograms were recorded using
a TA Instruments Q2000 calorimeter (TA Instruments, New Castle,
Delaware, USA). For analysis 4–6 mg of sample was accurately
weighed and sealed in an aluminium pan (hermetic and pinholed
pans used as appropriate). Samples were heated under nitrogen
gas (ﬂow rate 50 mL/min) at a rate of 2 C/min, amplitude  0.212
C and a period of 40 s. Calibration was performed using n-
octadecane, benzoic acid, indium, and tin. Samples were analysed
in triplicate unless stated otherwise. Data analysis was carried out
with TA Universal Analysis software.
2.5. Powder X-ray diffraction (PXRD)
Powder X-ray Diffraction was carried out using a Rigaku 600
Miniﬂex diffractometer (Rigaku, Tokyo, Japan), CuKa radiation,
operating power: 40 mV, 15 mA. Patterns were recorded over the
2u range 3–40 at a scan rate of 5/min.
2.6. In vitro drug release test
In vitro drug release was tested using the British Pharmacopoeia
method 2.9.3 dissolution test for solid dosage forms with the aid of
a Caleva 8ST dissolution apparatus (G.B. Caleva Ltd., UK). Samples
equivalent to 150 mg of isoniazid were loaded into Size 0 gelatine
capsules (Qualicaps Europe SA, Madrid) and placed into a metallic
sinker. The sinker was placed in a dissolution bath containing
900 mL 0.1N HCl (pH: 1.2  0.2) at 37.0  0.5 C and a paddle speed
of 50 rpm. At predetermined time intervals, a 10 mL sample was
withdrawn from each vessel and replaced with the same amount of
fresh media to ensure constant volume of medium within the
vessel. The concentration of drug in the dissolution medium was
measured by UV–vis spectrometry (Jenway 6305 Spectrophotom-
eter; Bibby Scientiﬁc, Staffordshire, UK) at 263 nm. No interference
from the polymers used or gelatine capsules was observed at this
wavelength. Experiments were carried out in triplicate and
dissolution proﬁles are plotted as mean percentage drug release
 standard deviation.
2.7. Rodent Brief Access Taste Aversion (BATA) testing
A total of ten adult male Sprague–Dawley rats (Charles-River,
Kent, UK) were used for these experiments. They were housed in
pairs in a room maintained at 21  2 C with 55 10% relative
humidity and with a 12:12 h light/dark cycle. Animals had free
access to chow (Harlan, Oxon, UK) and tap water except for training
and testing periods where a 22 h water-restriction schedule
occurred (g 2.7.2). Throughout the experiments, daily food and
water consumption were monitored. As a safety and welfare
measure, each rat was weighed daily to ensure that their weight
did not drop below 85% of their free-feeding weight. All the
procedures were carried out in accordance with Animals (Scientiﬁc
Procedures) Act 1986 (Project Licence PPL 70/7668).
2.7.1. Taste solutions
In order to establish an aversiveness – concentration standard
curve, six solutions of isoniazid in deionised water ranging from
1.25 mg/mL–40 mg/mL were prepared. They were prepared on the
day of the study and presented to the rats at room temperature.Please cite this article in press as: A.V. Keating, et al., Solid state charac
extrudates of isoniazid for paediatric administration, Int J Pharmaceut 2.7.2. BATA experiment
Each mildly water deprived rat was placed individually in the
lickometer “Davis MS-160” (DiLog Instruments, Tallahassee,
Florida, USA) for a maximum of 40 min (session-length). After
each session, the rats received tap water for rehydration in their
home cage. The rats received a ﬁrst training session where the
shutter was continuously open presenting a single tube containing
deionised water. This session was followed by a second training
session where they were presented to sixteen moving tubes
containing deionised water, with the shutter opening for 8 s and
closing. The training sessions were followed by two testing
sessions during which each rat was presented for 8 s with either
deionised water or one of the six concentrations of drug in a
randomised order. Each sample was intercepted by a water rinse to
minimise carry over effects.
2.7.3. Data analysis
The normality of the data was checked with the Shapiro-Wilk
test. As the data were not normally distributed, the Kruskal-Wallis
test was performed to check if there were signiﬁcant differences in
the number of licks between the different concentrations tested.
The same test was done to check which concentrations elicited a
number of licks signiﬁcantly different compared to deionised
water. When signiﬁcant, post-hoc analysis was carried out with
Gao et al. non-parametric multiple test (Gao et al., 2008). An IC50
value which corresponds to the concentration of the drug that
inhibits 50% of the maximum number of licks compared to the
reference, deionised water, was calculated with an Emax model
(Sheng et al., 2016; Soto et al., 2015).
2.8. Solubility studies
The solubility of isoniazid was assessed in both distilled water
and simulated salivary ﬂuid (SSF) at pH 7.4 adapted from Hughes
and Gehris (2003) (Table 2). An excess amount of pure isoniazid
was added to 30 mL distilled water or SSF at 37  0.5 C and shaken
for 72 h until equilibrium was reached. The samples were then
ﬁltered using 0.22 mm ﬁlters (Merck-Millipore, Cork, Ireland) and
the absorbance of the samples were recorded at 263 nm using a
Jenway 6305 UV–vis Spectrophotometer (Bibby Scientiﬁc, Staf-
fordshire, UK).
2.9. Simulation of drug release in the oral cavity
Dissolution testing was carried out to simulate the dissolution
of pure isoniazid and the polymeric formulations in the oral cavity.
Exposure of the drug/formulations to oral cavity conditions was
mimicked by 5 min drug contact with 5 mL of SSF at pH 7.4.
Samples were manually withdrawn at 0.5, 1, 1.5, 2, 2.5, 3 and 5 min
and replaced with fresh media. A temperature of 37  0.5 C and a
rotational speed of 50 rpm (magnetic stirring) were maintained
during the experiment. Samples were ﬁltered through 0.22 mm
ﬁlters (Merck-Millipore, Cork, Ireland) and analysed by UV–vis
Spectrometry (Jenway 6305 Spectrophotometer; Bibby Scientiﬁc,
Staffordshire, UK) at 263 nm.Distilled water to 1 L
terisation and taste masking efﬁciency evaluation of polymer based
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Table 3
Results of drug loading experiments for isoniazid containing formulations. Drug
loading is given as mean percentage  standard deviation.
Polymer Expected Drug Load (% w/w) Actual Drug Load (% w/w)
Soluplus 20 20.38  0.71
30 29.47  1.58
Eudragit E-PO 20 20.13  0.48
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Drug release was compared to the IC50 value for isoniazid
obtained from BATA testing to determine whether the formula-
tions were likely to be aversive or not.
2.10. Electronic tongue assessment
The TS-5000Z (Insent Inc., Atsugi-shi, Japan) was equipped with
four lipid membrane sensors and two corresponding reference
electrodes (PPM Instruments, West Sussex). Three of the sensors
represent bitterness, bitterness sensor 1 (SB2AC0), bitterness
sensor 2 (SB2AN0) and bitterness sensor 3 (SB2C00). The fourth
sensor represents astringency (SB2AE1). Reference solution used for
cleaning and as a reference solution was prepared by dissolving
30 mmol/L potassium chloride and 0.3 mmol/L tartaric acid in
distilled water. Negatively charged washing solution used for
washing the negatively charged sensors (SB2AC0 and AB2AN0)
was prepared by diluting absolute ethanol to 30% with distilled
water and adding 100 mmol/L hydrochloric acid. Positively charged
washing solution used for washing the positively charged sensors
(SB2C00 and SB2AE1) was prepared by diluting absolute ethanol to
30% and adding 100 mmol/L potassium chloride and 10 mmol/L
potassium hydroxide. A sensor check was conducted routinely
before each measurement to ensure that the sensors were working
within the correct mV range. Each measurement cycle consisted of
measuring a reference solution (Vr), followed by the sample
solution (Vs), a short (2  3 s). The sensor output for taste (relative
value, R value) was calculated relative to the preliminary sensor
response to the reference solution (Vr).
R ¼ Vs  Vr ð1Þ
The entire measurement procedure was performed for all
samples and repeated afterwards up to four times. For further data
treatment the ﬁrst run was discarded (as recommended by Insent)
to enable conditioning of sensors.
2.10.1. Sample preparation for electronic tongue
The e-tongue can only assess the taste of liquid solutions.
Therefore when assessing the taste of solid formulations (as is the
case with hot melt extrudates) it is necessary to use ‘taste extracted
water’. The dose unit of isoniazid was set at 150 mg. For taste
evaluation 20 dose units (equivalent to 3 g isoniazid) were added to
100 mL of 10 mmol potassium chloride solution at 37 C and gently
stirred for 1 min. This represents a concentration of one dose in
5 mL which is suitable for taste assessment as there is only slight
dilution of the sample (Preis et al., 2012). The mixture was then
ﬁltered through 0.22 mm ﬁlters (Merck-Millipore, Cork, Ireland),
removing any suspended particles. This ‘taste extracted liquid’ was
then assessed using the measurement procedure described in
Section 2.10.2.
2.10.2. Data analysis
The sensor signal results were evaluated using Principal
Component Analysis (PCA). In PCA, the dataset is projected onto
the space spanned by the vectors called principal components
which correspond to the maximum variance of the dataset (Abdi
and Williams, 2010). Using PCA the most important information
contained in the raw data could be transformed into the ﬁrst
principal component (PC-1) and the second most important is
transformed into the second principal component (PC-2). Plotting
of PC-1 versus PC-2 gives a map which allows the assessment of
similarities and differences between different samples. Differences
between samples were assessed by determining the Euclidean
distance between them after multivariate data analysis. EuclideanPlease cite this article in press as: A.V. Keating, et al., Solid state charac
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d p; qð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Xn
i¼1
pi  qið Þ2
vuut ð2Þ
All data analysis was carried out using OriginPro 9.1 (Origin Lab,
Massachusetts, USA).
3. Results and discussion
3.1. Hot melt extrusion
Hot melt extrusion processing of all Soluplus based formula-
tions was carried out at 140 C and 50 rpm. Opaque extrudates
were formed at both 20% w/w and 30% w/w drug loading.
Increasing the drug loading did not appear to have any effect on the
processability of the mixture. All Eudragit E-PO based formulations
were processed at 130 C and 50 rpm. At both 20% w/w and 30% w/
w drug loading uniform, opaque off-white extrudates were
formed. As found for the Soluplus based systems, increasing the
drug loading did not appear to have any effect on the processability
of the mixture.
3.2. Physicochemical characterisation of extrudates
The drug loading of the formulations was assessed to ensure
that the drug was not being degraded in situ during the extrusion
process. The results of these experiments are given in Table 3. The
drug loading was found to be within the expected range for all
formulations, indicating that degradation was not occurring.
Fig. 1 shows the DSC thermograms of the Soluplus based
extrudates. The Tg of each of these formulation was lower than the
Tg of Soluplus alone (70.4  2.2 C) indicating the presence of
amorphous drug in these formulations. As drug loading is
increased, the Tg of the formulations decreases, i.e. 49.6  2.8 C
and 42.2  3.6 C for the 20% and 30% drug loaded systems
respectively. This is likely to be due to the drug exerting a
plasticization effect on the polymer. Soluplus is a hygroscopic
polymer, however thermogravimetric analysis of both the pure
polymer and extrudates (data not shown) demonstrated that water
content of the samples was negligible, thus the decrease in Tg is
solely due to the plasticization effect of the drug.
For the 20% extrudates a single Tg was observed for indicating
that the drug is in a fully amorphous form. Typically, to produce
amorphous solid dispersions the mixture processed at temper-
atures higher than the Tm of the drug which ensures complete
conversion of the crystalline drug to the amorphous form (Liu et al.,
2013). However, in this case conversion of the drug to the
amorphous form is seen at temperatures over 30 C below the Tm of
the drug. This is most likely due to isoniazid being solubilised in the
molten Soluplus during the extrusion process.
The 30% extrudates on the other hand show a cold crystal-
lisation of amorphous material with an onset of 90.4 1.9 C and
peak at 98.2 1.3 C followed by melting of crystalline material30 29.72  0.32
terisation and taste masking efﬁciency evaluation of polymer based
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Fig. 1. DSC thermograms of Soluplus based extrudates (a) 20% w/w drug loading (reversing heat ﬂow). (b) 30% w/w drug loading (reversing heat ﬂow); (c) 30% w/w drug
loading (total heat ﬂow); processed at 140 C and 50 rpm (pinholed pans).
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reﬂect the drug content exceeding the loading at which miscibility
is stable, at least in terms of recrystallization induced by
temperature ramping under the conditions used here. The glass
transition is most easily envisaged in the reversing heat ﬂow
(Fig. 1b).
The PXRD patterns of pure isoniazid and the Soluplus based
extrudates are displayed in Fig. 2. The diffraction pattern of the 20%
w/w drug loaded extrudates show an amorphous halo with no
distinct crystalline peaks. This is in agreement with the results of
the DSC experiments which show no melting peak associated with
crystalline isoniazid. The 30% w/w drug loaded extrudates also
have an amorphous halo with no distinct crystalline peaks. This
shows that the extrudate as produced is completely amorphous
and only undergoes recrystallisation on heating (as per the DSC
results).
The Tg of the 20% and 30% Eudragit E-PO based extrudates were
determined to be 52.9  0.4 C and 53.9  0.7 C respectively
(Fig. 3). This represents a very similar value to that of the polymer
alone (55.3  0.5 C). A melting peak is observed at approximately
170 C for both formulations which can be attributed to melting of
crystalline isoniazid, which has a Tm of 170.83  0.03 C. The
sharpness of the melting peak and the similarity of the meltingFig. 2. PXRD of (a) pure Isoniazid (b) 20% w/w drug loa
Please cite this article in press as: A.V. Keating, et al., Solid state charac
extrudates of isoniazid for paediatric administration, Int J Pharmaceut point to the drug alone indicate little or no interaction between the
drug and polymer.
The diffraction patterns of Eudragit E-PO based extrudates and
pure isoniazid are given in Fig. 4. The diffraction patterns of the
Eudragit E-PO based formulations are characterized by a ‘bowed’
baseline with many distinct crystalline peaks which can be
attributed to the presence of crystalline isoniazid at both
concentrations (in agreement with DSC results).
3.3. In vitro drug release
In vitro drug release studies were carried out to determine the
rate of drug release from these formulations under GI conditions.
Rapid dissolution of pure isoniazid is seen in 0.1N HCl, with 100% of
the drug being released within 5 min. As stated previously, the aim
of this study was to taste mask the drug without altering the
release proﬁle of the drug. Therefore it was intended that a rapid
dissolution proﬁle would be observed for the extruded formula-
tions.
Fig. 5a shows the dissolution proﬁle of the Soluplus based
formulations compared to pure isoniazid. The 20% formulation
demonstrates a drug release of 19.2% after 5 min while drug release
from the 30% formulation at the same time point is signiﬁcantly
lower at just 2.0%. After 10 min the most rapid drug release is againded extrudate; (c) 30% w/w drug loaded extrudate.
terisation and taste masking efﬁciency evaluation of polymer based
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Fig. 3. DSC thermograms showing total heat ﬂow (solid line) and reversing heat ﬂow (dashed line) of (a) 20% w/w EPO/Isoniazid extrudates; (b) 30% w/w EPO/Isoniazid
extrudates processed at 130 C and 50 rpm (pinhole pans).
6 A.V. Keating et al. / International Journal of Pharmaceutics xxx (2017) xxx–xxx
G Model
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drug load, compared to just 41.1% respectively from the 30%
formulation. Complete drug release from both formulations is
observed after 45 min. A lag phase is observed in the ﬁrst ﬁve
minutes of dissolution of these formulations. This may be due to
hydrogens of the hydrazine group of isoniazid forming hydrogen
bonds with the carbonyl groups of either the caprolactam or
acetate group of Soluplus, retarding the initial release of the drug.
The dissolution proﬁles of the Eudragit E-PO formulations
compared to pure isoniazid are given in Fig. 5b. A similar trend to
that observed for the Soluplus based formulations was also
observed for the Eudragit E-PO formulations with the most rapidFig. 4. PXRD of (a) pure isoniazid; (b) 20% w/w Eudragit E-PO/isoni
Please cite this article in press as: A.V. Keating, et al., Solid state charac
extrudates of isoniazid for paediatric administration, Int J Pharmaceut drug release being observed for the 20% drug loaded formulation
with 100% drug release within 5 min. The 30% drug loaded
formulation achieves 100% drug release within 15 min. Eudragit E-
PO, whilst insoluble above pH 5 is extremely soluble in acidic
media, thus leading to rapid release of the drug under these
conditions. It can also be seen that the 20% formulations have very
similar release proﬁle to that of the pure drug alone. While
Eudragit E-PO also contains carbonyl groups with could form
hydrogen bonding interactions with isoniazid, they are signiﬁ-
cantly more sterically hindered than those found in Soluplus,
which may explain why no lag phase is observed for the
formulations.azid extrudate; (c) 30% w/w Eudragit E-PO/isoniazid extrudate.
terisation and taste masking efﬁciency evaluation of polymer based
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Fig. 5. Dissolution proﬁle of (a) Soluplus/isoniazid extrudates and (b) Eudragit E-PO/isoniazid extrudates compared to the dissolution proﬁle of pure isoniazid.
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The aversiveness of pure isoniazid was assessed using the
rodent BATA model and a dose-aversiveness response curve wasFig. 6. Average number of licks recorded in 8 s (SEM) as a fun
Please cite this article in press as: A.V. Keating, et al., Solid state charac
extrudates of isoniazid for paediatric administration, Int J Pharmaceut established (Fig. 6). For isoniazid, all except the two lowest
concentrations (1.25 mg/mL and 2.5 mg/mL) were statistically
different from water (p = 0.53 and p = 0.41). Isoniazid was found to
have a clear aversive taste that could be quantiﬁed by a calculatedction of concentration (mg/mL) for isoniazid (n = 10 rats).
terisation and taste masking efﬁciency evaluation of polymer based
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Fig. 7. Dissolution proﬁle of isoniazid and formulations in simulated salivary ﬂuid (SSF) at pH 7.4 and 37 C. Dashed line indicates IC50 value of isoniazid obtained from BATA
testing (11.1 mg/mL).
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to be 11.1 mg/mL. Comparing this to a highly bitter compound such
as quinine hydrochloride which has an IC50 value of 0.019 mg/mL
(Soto et al., 2015), isoniazid can be classiﬁed as a weakly bitter
compound.
3.5. Solubility studies
The saturated solubility of isoniazid was measured in both
distilled water and SSF (pH 7.4) at 37  0.5 C. The saturated
solubility of isoniazid in distilled water was found to be
1.92  0.07 g/mL. The saturated solubility of isoniazid in SSF was
found to be signiﬁcantly higher at 2.94  0.03 g/mL. The solubility
of a drug is intrinsically linked to its taste, as only drug in solution
can interact with the taste buds and produce a taste response.Fig. 8. Principal Component Analysis (PCA) of sensor responses after 1 min of all extruda
using output values of 3 bitter taste sensors (AC0, AN0, C00) and astringency sensor (A
Please cite this article in press as: A.V. Keating, et al., Solid state charac
extrudates of isoniazid for paediatric administration, Int J Pharmaceut 3.6. Simulation of drug release in the oral cavity
Biorelevant dissolution testing was carried in SSF out to assess
the amount of drug that would likely be released under in the oral
cavity in vivo. The results are shown in Fig. 7. It can be seen that
extremely rapid drug release is observed for pure isoniazid with
100% of the drug being released after 30 s. The high solubility of
isoniazid in both distilled water and SSF coupled with rapid
dissolution of isoniazid under simulated oral conditions indicate
that this will be a challenging drug to taste mask as it can easily
come into contact with the taste buds and produce a bitter taste
response. The amount of drug released was compared to the IC50
value for isoniazid obtained from BATA testing of 11.1 mg/mL.
The Eudragit E-PO extrudates showed very little drug release up
to 5 min with drug release remaining well below the IC50 value at
all time points. The total drug release from the formulations was
1.33  0.40 mg/mL and 1.55  0.57 mg/mL for the 20% and 30% drugtes compared with their physical mixtures and isoniazid alone. The PCA map is built
E1).
terisation and taste masking efﬁciency evaluation of polymer based
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isoniazid is likely to be adequately masked by these formulations.
The 20% Soluplus formulation signiﬁcantly retards the release of
the drug remaining below the IC50 for up to 4 min, while the 30%
Soluplus formulation exceeds the IC50 value after just 1.5 min,
indicating that this is likely to be the most aversive formulation.
The difference in drug release between the Soluplus and Eudragit
E-PO based formulations can be attributed to the difference in
water solubility of the polymers. Soluplus is a highly water soluble
polymer (BASF Group, 2010) which allows it to dissolve rapidly in
the oral cavity and thus release a large amount of drug. Eudragit E-
PO on the other hand is only soluble below pH 5 (Evonik Industries,
2014) meaning it is poorly soluble in the oral cavity, leading to very
little drug release from these formulations.
Previous work on the correlation between the rat BATA model
and human responses have suggested than an offset of one half log
unit of concentration may be observed between the IC50 value
obtained from BATA testing and the EC50 value obtained from
human testing (Devantier et al., 2008; Rudnitskaya et al., 2013).
The EC50 is the concentration of drug which elicits half the
maximum taste response in humans and may be directly compared
to IC50 values. Taking into account the potential ‘worst case
scenario’ in which the human EC50 is a half log unit of
concentration below the obtained IC50 this would result in an
EC50 value of 3.52 mg/mL. For the Soluplus based formulations this
would mean that the drug release from the formulations would
exceed the EC50 in less than 30 s, thus they would not effectively
mask the taste of the drug. Conversely, the Eudragit E-PO based
formulations would still remain well below the estimated EC50 at
all times as the maximum drug release from the formulations was
1.33  0.40 mg/mL and 1.55  0.57 mg/mL for the 20% and 30% drug
loaded extrudates respectively. This indicates that, even in this
worst case scenario, the bitter taste of the drug would still be well
masked by the Eudragit E-PO based formulations.
3.7. Electronic tongue
The taste of the formulations was also assessed using the Insent
electronic tongue. As noted in Section 2.10.2, the electronic tongue
can only assess the taste of liquids, thus for solid dosage forms it is
necessary to use ‘taste extracted water’ i.e. the samples were
stirred in 10 mmol potassium chloride solution for 1 min and the
taste of the resulting solution was assessed. Principal component
analysis was used to build a map from the sensor responses of the
four sensors used for taste assessment (Fig. 8). Solutions of pure
isoniazid are located on the upper left hand side of the map.
Euclidean distances were calculated to determine the differences
between the pure drug, physical mixtures, placebo and extrudates,
these are given in Table 4. The greater the Euclidean distance
between the pure drug and the formulation, the greater the
difference in taste.Table 4
Euclidean distances from each formulation, placebo and physical mixture to pure
isoniazid. Values are calculated from cluster centres. The greater the Euclidean
distance between the pure drug and formulation the greater the difference in taste.
Polymer Drug Loading (%w/w) Euclidean Distance to Pure Isoniazid
Placebo Physical Mixture Extrudate
Soluplus 20 12.27 1.87 4.51
30 13.93 0.77 0.72
Eudragit E-PO 20 5.42 5.63 8.97
30 5.41 5.60 8.76
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Section 3.6 it would be expected that the Eudragit E-PO based
extrudates would have a greater Euclidean distance from pure
isoniazid than the Soluplus extrudates and this is indeed the case.
Euclidean distances for the Soluplus based extrudates decrease
from 4.51 for the 20% drug loaded extrudates to 1.32 for the 30%
drug loaded extrudates in accordance with the increase in drug
release from these formulations after 1 min. The physical mixtures
of Soluplus and isoniazid show smaller Euclidean distances than
the extrudates, indicating that processing by hot melt extrusion
improves the taste masking efﬁciency of the polymer.
Soluplus is a water soluble polymer (BASF Group, 2010)
meaning it can readily dissolve in the oral cavity, allowing release
of the drug. The DSC and PXRD analysis of the extrudates indicates
that the Soluplus based formulations are amorphous. Amorphous
solid dispersions have long been used to increase the dissolution
rate of drugs (Vasconcelos et al., 2007). The amorphous nature of
the drug, coupled with the high water solubility of Soluplus leads
to a large amount of drug being released in the oral cavity and thus
poor taste masking.
The Eudragit E-PO based formulations show a better taste
masking efﬁciency which is to be expected given that the drug
release from these formulations under simulated oral conditions is
signiﬁcantly lower than that of Soluplus formulations. The greatest
overall taste masking efﬁciency is observed for the 20% drug loaded
Eudragit E-PO extrudates with a Euclidean distance of 8.97. This is
to be expected given that this is the formulation with the lowest
amount of drug release after 1 min. The 30% Eudragit E-PO
extrudate also has good taste masking efﬁciency with a Euclidean
distance of 8.76. Again, the physical mixtures showed signiﬁcantly
lower Euclidean distances than the corresponding extrudates,
demonstrating the usefulness of hot melt extrusion as a technique
for taste masking. Ranking the formulations in order of taste
masking efﬁciency it was found that;
20% Eudragit E-PO > 30% Eudragit E-PO > 20% Soluplus > 30%
Soluplus.
The observed difference in taste masking efﬁciency between
the two polymeric carriers can be attributed to their different
water solubilities. As discussed in Section 3.3, Soluplus is highly
water soluble (BASF Group, 2010), while Eudragit E-PO is only
soluble below pH 5 (Evonik Industries, 2014). The pH of the oral
cavity is generally between 6.8–7.4 (Aframian et al., 2006).
Eudragit E-PO is insoluble under these conditions, although it
can swell, releasing a small amount of drug. Soluplus is freely
soluble at the pH values found in the oral cavity, thus allowing a
large amount of drug (in excess of threshold bitterness value) to be
released.
The taste masking efﬁciency was evaluated using two different
methods, i.e. simulated oral dissolution and electronic tongue. The
rank order of formulations in terms of aversiveness was found to be
the same for both methods, with the 20% Eudragit E-PO being the
least aversive and 30% Soluplus being the most aversive. The
mutual validation of the two methods is particularly encouraging
as it demonstrates the utility of both for formulation development.
4. Conclusions
In summary, HME was successfully used to produce polymeric
formulations of isoniazid with drug loadings of up to 30%. Rapid in
vitro release of isoniazid is observed from Eudragit E-PO
formulation at pH 1.2, particularly the 20% drug loaded formula-
tion which has a release proﬁle similar to that of isoniazid alone.
BATA testing was used to determine an IC50 value for isonaizid of
11.1 mg/mL which was used as a threshold bitterness value for tasteterisation and taste masking efﬁciency evaluation of polymer based
(2017), http://dx.doi.org/10.1016/j.ijpharm.2017.07.008
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IJP 16823 No. of Pages 11assessment of the formulations. In vitro taste assessment of the
formulations indicated that the bitter taste of isoniazid was most
effectively masked by Eudragit E-PO due to the fact that Eudragit E-
PO is insolublle below pH 5, thus preventing release of the drug in
the mouth. Overall, the 20% drug loaded Eudragit E-PO formulation
is the most promising to mask the bitter taste of isoniazid without
signifcantly affecting dissolution performance and, by extension,
the bioavailability of the of the drug.
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